US drug companies Amylin and Alkermes announced on Friday that they received US FDA approval for their once-weekly injection, BYDUREON (exenatide extended-release for injectable suspension). Similar to Victoza (liraglutide (rDNA origin) injection), BYDUREON is a GLP-1 receptor agonist and the once-weekly version of BYETTA (twice-daily exenatide), useful for type 2 diabetic patients not achieving sufficient [...]

Technology companies are historically known as being on the leading edge of research, and now many are looking to diabetes management as an area of interest. They’re taking a fresh approach on the disease that affects a growing number of people, and are using technology to integrate better diabetes care into patients lives. California-based company [...]

In a study released Tuesday in the journal Diabetes Care, it was revealed that diabetic patients who received at least monthly care reached their targets for blood glucose, blood pressure, or cholesterol sooner than those who were monitored less frequently. Monthly care patients were found to reach their goal in 3.9 weeks, whereas patients who [...]

In a statement released on January 18, 2012, Health Canada and Novartis issued a warning regarding the use of products containing the direct renin inhibitor, aliskiren (Rasilez and Rasilez HCT), in combination with angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARBs), especially in diabetic patients. The results of the Aliskiren Trial in Type 2 [...]

The fried chicken-loving, southern chef and star of Paula’s Best Dishes, Paula Deen, recently opened up to USA Today about her diagnosis of Type 2 Diabetes. Deen, known best for her high-calorie southern comfort food, was diagnosed with diabetes in 2008, but waited until this year to announce the news because she says, “My knowledge [...]